RECORD // Company

Edesa Biotech, Inc.

Formerly: Stellar Biotechnologies, Inc.

Built 2026-11-22T03:39:46Z from public sources · JSON · Open the company profile

ASK THE RECORDS

Ask

COMPANY

Records for this company (1 joined by official identifier)

Every record below is joined to this company by a hard identifier: its SEC registrant record or its GLEIF ownership tree. Each line says how. Built 2026-11-18 13:42:42. Beta: records that match only by name are held apart until name matching is verified.

SEC EDGAR (1)
Records under a former name (1)

The name on these records was this company's name in the past (SEC name history). An old name can also belong to an unrelated organization, so they are shown apart and are not counted above.

Matched by name only, not merged (1)

These records carry the same exact name as this company, but a name alone is not proof, so Seraphix holds them apart until name matching is verified (score due 11-21).

  • Edesa Biotech Inc. · Ctgov · same registered legal name as 'Edesa Biotech, Inc.' Possible match based on name, not a shared identifier. Compare the records. Compare

2 VALUES · 10-Q · EACH LINKS TO ITS FILING

Latest quarter

Latest report: 10-Q for the period ended 2026-06-30, filed 2026-08-13 · accession 0001171843-26-005502

ItemValuePeriodFormFiledAccessionReport
Net income (loss)$-5,407,6113 months ended 2026-06-3010-Q2026-08-130001171843-26-0055022026-11-22 03:39 UTCReport an error
Cash and cash equivalents$10,300,000at 2026-06-3010-Q2026-08-130001171843-26-0055022026-11-22 03:39 UTCReport an error

Negative as reported in the filing.

Not in this report's XBRL: Revenue, Interest expense.

Values as filed in XBRL (SEC company facts); quarterly values are the filer's 3-month figures, never derived.

IDS

Identifiers

SEC CIK
0001540159
Ticker
EDSA
CUSIP
27966L306
Record ID
sx:sec:0001540159

OTHER SITES · YOUR CLICK · THEY SHOW THEIR OWN DATA

Open in

Open in…

Each link opens the other site in a new tab, with this company filled in. That site shows its own data under its own terms; Seraphix stores none of it. Seraphix counts clicks per link, nothing about who clicked.

33 FACTS · EACH LINKS TO ITS FILING

Facts

FactValueAs ofSourceRetrievedReport
SEC entity typeoperating2026-11-17SEC EDGAR company profile2026-11-22 03:39 UTCReport an error
SIC industry2834 Pharmaceutical Preparations2026-11-17SEC EDGAR company profile2026-11-22 03:39 UTCReport an error
State of incorporationA12026-11-17SEC EDGAR company profile2026-11-22 03:39 UTCReport an error
Fiscal year end (MMDD)09302026-11-17SEC EDGAR company profile2026-11-22 03:39 UTCReport an error
Business addressC/O FASKEN MARTINEAU DUMOULIN LLP, 333 BAY STREET, SUITE 2400, TORONTO, M5H 2T62026-11-17SEC EDGAR company profile2026-11-22 03:39 UTCReport an error
ExchangesNasdaq2026-11-17SEC EDGAR company profile2026-11-22 03:39 UTCReport an error
Net income (loss) (fiscal year ended 2025-09-30)$-7,185,5232025-09-3010-K, XBRL NetIncomeLoss2026-11-22 03:39 UTCReport an error
Total assets (at 2025-09-30)$13,530,5182025-09-3010-K, XBRL Assets2026-11-22 03:39 UTCReport an error
Stockholders' equity (at 2025-09-30)$12,451,9822025-09-3010-K, XBRL StockholdersEquity2026-11-22 03:39 UTCReport an error
Cash and cash equivalents (at 2025-09-30)$10,800,0002025-09-3010-K, XBRL CashAndCashEquivalentsAtCarryingValue2026-11-22 03:39 UTCReport an error
Operating cash flow (fiscal year ended 2025-09-30)$-7,322,2622025-09-3010-K, XBRL NetCashProvidedByUsedInOperatingActivities2026-11-22 03:39 UTCReport an error
Operating lease liabilities (at 2024-09-30)$19,8672024-09-3010-K, XBRL OperatingLeaseLiability2026-11-22 03:39 UTCReport an error
Form D total offering amount (D filed 2026-06-26)$3,500,0002026-06-26D2026-11-22 03:39 UTCReport an error
Form D total amount sold (D filed 2026-06-26)$3,499,9862026-06-26D2026-11-22 03:39 UTCReport an error
Form D industry groupBiotechnology2026-06-26D2026-11-22 03:39 UTCReport an error
Form D revenue rangeDecline to Disclose2026-06-26D2026-11-22 03:39 UTCReport an error
Form D date of first sale2026-06-162026-06-26D2026-11-22 03:39 UTCReport an error
8-K Item 8.01, Other Events (filed 2026-11-17)On November 17, 2026, Edesa Biotech, Inc. (the “Company”) announced that the European Commission has granted orphan designation to its investigational drug paridiprubart for the treatment of Acute Respiratory Distress Syndrome (“ARDS”). The designation follows a positive opinion from the European Medicines Agency’s Committee for Orphan Medicinal Products, recognizing both the high mortality rates in ARDS and the need for new treatment options for patients. Orphan drug designation in the European Union provides important regulatory incentives, including reduced development fees, potential market exclusivity following approval, and enhanced development efficiency, which may help streamline…2026-11-17SEC EDGAR 8-K 0001171843-26-007511 (text as filed, excerpt)2026-11-22 03:39 UTCReport an error
8-K Item 1.01, Entry into a Material Definitive Agreement (filed 2026-11-09)Collaboration and License Agreement On November 8, 2026, Edesa Biotech, Inc., together with its wholly owned subsidiaries (the “Company”), entered into a Collaboration and License Agreement (the “License Agreement”) with Kyorin Pharmaceutical Co., Ltd. (“Kyorin”). Pursuant to the License Agreement, the Company granted Kyorin an exclusive, royalty-bearing license, with the right to grant sublicenses subject to the terms of the License Agreement, to develop and commercialize the Company’s anti-TLR4 monoclonal antibody, paridiprubart (EB05), for the treatment of acute respiratory distress syndrome (“ARDS”) in Japan (the “Licensed Territory”), subject to the terms of the License Agreement. The…2026-11-09SEC EDGAR 8-K 0001171843-26-007242 (text as filed, excerpt)2026-11-22 03:39 UTCReport an error
8-K Item 1.02, Termination of a Material Definitive Agreement (filed 2026-11-09)On November 8, 2026, the Company provided notice to H.C. Wainwright & Co., LLC (“HCW”) of the termination of the At The Market Offering Agreement, dated October 4, 2024 (the “ATM Agreement”), between the Company and HCW, effective November 16, 2026. The ATM Agreement provided for the offer and sale of the Company’s common shares, without par value (“Common Shares”), from time to time through HCW as its sales agent and/or principal, subject to the maximum aggregate dollar amount registered pursuant to the applicable prospectus supplement. Sales of Common Shares through HCW were to be made (A) in negotiated transactions with the consent of the Company or (B) by any other method permitted by…2026-11-09SEC EDGAR 8-K 0001171843-26-007242 (text as filed, excerpt)2026-11-22 03:39 UTCReport an error
8-K Item 7.01, Regulation FD Disclosure (filed 2026-11-09)On November 9, 2026, the Company issued a press release announcing the transaction contemplated by the License Agreement. A copy of the press release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K and incorporated in this Item 7.01 by reference. The information in this Item 7.01, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth…2026-11-09SEC EDGAR 8-K 0001171843-26-007242 (text as filed, excerpt)2026-11-22 03:39 UTCReport an error
8-K Item 5.02 (filed 2026-10-23)Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On October 23, 2026, the Board of Directors (the “Board”) of Edesa Biotech, Inc. (the “Company”), upon the recommendation of the Compensation Committee of the Board, approved increases in the annual base salaries of Dr. Pardeep Nijhawan, the Company’s Chief Executive Officer, from $357,696 to $657,423, Dr. Michael Brooks, the Company’s President, from $335,340 to $591,681, and Peter Weiler, the Company’s Chief Financial Officer, from $300,000 to $525,938, in each case pursuant to their respective employment agreements with the Company and…2026-10-23SEC EDGAR 8-K 0001171843-26-006794 (text as filed, excerpt)2026-11-22 03:39 UTCReport an error
8-K Item 8.01, Other Events (filed 2026-10-15)On October 15, 2026, Edesa Biotech, Inc. (the “Company”) reported that the U.S. Food and Drug Administration (“FDA”) has cleared the Company's Investigational New Drug (“IND”) application for its Phase 2 clinical study of EB06 in vitiligo, enabling the Company to expand recruitment to the United States. Patient recruitment is underway in Canada and the first U.S. investigational sites are expected to begin enrolling subjects next quarter. The Company anticipates that topline data will be available fourth quarter 2027. The double-blind, placebo-controlled clinical study is evaluating EB06, a monoclonal antibody targeting CXCL10, in up to 80 adults with moderate-to-severe nonsegmental…2026-10-15SEC EDGAR 8-K 0001171843-26-006647 (text as filed, excerpt)2026-11-22 03:39 UTCReport an error
Largest institutional holder #1 (13F as filed): Velan Capital Investment Management LP$6,727,5752026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 03:39 UTCReport an error
Largest institutional holder #2 (13F as filed): Rubric Capital Management LP$5,443,0352026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 03:39 UTCReport an error
Largest institutional holder #3 (13F as filed): PERCEPTIVE ADVISORS LLC$4,579,1332026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 03:39 UTCReport an error
Largest institutional holder #4 (13F as filed): MILLENNIUM MANAGEMENT LLC$4,567,0362026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 03:39 UTCReport an error
Largest institutional holder #5 (13F as filed): Stonepine Capital Management, LLC$3,190,8072026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 03:39 UTCReport an error
Largest institutional holder #6 (13F as filed): Boxer Capital Management, LLC$1,666,6502026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 03:39 UTCReport an error
Largest institutional holder #7 (13F as filed): VANGUARD CAPITAL MANAGEMENT LLC$665,3512026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 03:39 UTCReport an error
Largest institutional holder #8 (13F as filed): GEODE CAPITAL MANAGEMENT, LLC$657,5862026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 03:39 UTCReport an error
Largest institutional holder #9 (13F as filed): JANE STREET GROUP, LLC$589,1412026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 03:39 UTCReport an error
Largest institutional holder #10 (13F as filed): VANGUARD FIDUCIARY TRUST CO$314,7772026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 03:39 UTCReport an error

EVERY DATED RECORD, NEWEST FIRST

Timeline

WHAT IS NOT HERE

Gaps

SOURCES AND LICENSE

Sources

CC BY 4.0 -- credit Seraphix Systems.

API

Use this record

Records are free to read and reuse under CC BY 4.0 -- credit Seraphix Systems. The same records as JSON: GET /v1/search?q= and GET /v1/record/<id> (without a key, up to 50 record lookups a day per visitor). No key: single records, pages, feeds and bulk files are free; cross-company search and the live stream cost $0.002 a call via x402. Free key: 100 calls a month, no card. Get a free key or a paid key; send Authorization: Bearer <key>.